LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iSpecimen
Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an
online marketplace for human biospecimens, today announced that
Christopher Ianelli, MD, PhD, CEO
and President of iSpecimen, will participate in the H.C. Wainwright
BioConnect Conference to be held virtually on January 10-13, 2022. Dr. Ianelli's corporate
presentation will be available on-demand starting Monday, January 10th at 7:00 a.m. ET.
For more information about the H.C. Wainwright BioConnect
Conference, or to schedule a one-on-one meeting with iSpecimen's
management, please contact your H.C. Wainwright representative
directly or KCSA Strategic Communications at
iSpecimen@kcsa.com.
About iSpecimen
iSpecimen offers an online marketplace
for human biospecimens, connecting life scientists in commercial
and non-profit organizations with healthcare providers that have
access to patients and specimens needed for medical discovery.
Proprietary, cloud-based technology enables scientists to
intuitively search for specimens and patients across a federated
partner network of hospitals, labs, biobanks, blood centers, and
other healthcare organizations. For more information about
iSpecimen, please visit www.ispecimen.com.
Forward-Looking Statements
This press release may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," believe," "estimate" and "continue" or similar words.
You should read statements that contain these words carefully
because they discuss future expectations and plans, which contain
projections of future results of operations or financial condition
or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risk factors contained in
the Company's filings with the Securities and Exchange Commission,
which are available for review at www.sec.gov. Forward-looking
statements speak only as of the date they are made. New risks and
uncertainties arise over time, and it is not possible for the
Company to predict those events or how they may affect the Company.
If a change to the events and circumstances reflected in the
Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
statements. Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Allison Soss
iSpecimen@kcsa.com
Media Contact
Kaitlynn
Cooney
For iSpecimen
kcooney@brodeur.com
609.351.5944
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ispecimen-to-participate-in-the-hc-wainwright-bioconnect-conference-on-january-10-13-2022-301453120.html
SOURCE iSpecimen Inc.